[HTML][HTML] Old and new oral anticoagulants: food, herbal medicines and drug interactions

…, A Ravani, D Sansaro, M Amato, JP Kitzmiller… - Blood reviews, 2017 - Elsevier
The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists
(VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important …

[HTML][HTML] Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

JP Kitzmiller, DK Groen, MA Phelps… - Cleveland Clinic journal …, 2011 - ncbi.nlm.nih.gov
Genetics may account for much of the variability in our patients’ responses to drug therapies.
This article offers the clinician an up-to-date overview of pharmacogenomic testing, …

Pharmacogenomics of statins: understanding susceptibility to adverse effects

JP Kitzmiller, EB Mikulik, AM Dauki… - Pharmacogenomics …, 2016 - Taylor & Francis
Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic
cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and …

Physician perspectives on education, training, and implementation of complementary and alternative medicine

SJ Patel, KJ Kemper, JP Kitzmiller - Advances in medical education …, 2017 - Taylor & Francis
Over recent decades, the demand for complementary and alternative medicine (CAM) has
continued to rise in the US. Like the practice of traditional Western medicine, CAM is …

[HTML][HTML] CYP3A4* 22 and CYP3A5* 3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

JP Kitzmiller, JA Luzum, D Baldassarre… - Pharmacogenetics …, 2014 - journals.lww.com
Objective Simvastatin is primarily metabolized by CYP3A4. A combined CYP3A4/5
genotype classification, combining the decrease-of-function CYP3A4* 22 and the loss-of-function …

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure

…, JP Jarvis, MF Christman, W Sadee, JP Kitzmiller - Pharmaceutical …, 2017 - Springer
Purpose This study examined whether a CYP2D6 polymorphism (CYP2D6*4) was related
to beta-blocker maintenance dose in patients with heart failure. Methods Logistic regression …

[PDF][PDF] GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals

JA Luzum, JP Kitzmiller, PJ Isackson, C Ma… - Cell metabolism, 2015 - cell.com
Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin
therapy. A polymorphism affecting the gene encoding glycine amidinotransferase (GATM …

[HTML][HTML] Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants

JA Talameh, JP Kitzmiller - Journal of pharmacogenomics & …, 2014 - ncbi.nlm.nih.gov
Statins are the most commonly prescribed drugs in the United States and are extremely effective
in reducing major cardiovascular events in the millions of Americans with hyperlipidemia…

[HTML][HTML] Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes

JP Kitzmiller, PF Binkley, SR Pandey, AM Suhy… - Discovery …, 2013 - ncbi.nlm.nih.gov
Indicated for treating hyperlipidemias and for the prevention of cardiovascular disease (CVD),
statins rank among the most commonly prescribed drug classes. While statins are …

Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations

…, RM Krauss, MW Medina, JP Kitzmiller - Journal of …, 2015 - journals.lww.com
Our objective was to evaluate the associations of genetic variants affecting simvastatin (SV)
and simvastatin acid (SVA) metabolism [the gene encoding cytochrome P450, family 3, …